Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

• DOI: 10.2337/dc13-0387
• Publication Date: 2013-06-05T03:46:19Z
• Authors: Ralph A. DeFronzo; Marcus Hompesch; Sreeneeranj Kasic...; Xiaoni Liu; Ying Hong; Marc Pfister; Linda A. Morrow; Bruce R. Leslie; David W. Boulton; Agatha Ching; Frank P. LaCreta; Steven C. Griffen
• Keywords: Dapagliflozin; Renal glucose reabsorption

To examine the effect of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on major components renal glucose reabsorption (decreased maximum reabsorptive capacity [TmG], increased splay, and reduced threshold), using pancreatic/stepped hyperglycemic clamp (SHC) technique.Subjects with type diabetes (n=12) matched healthy subjects underwent pancreatic/SHC (plasma range 5.5-30.5 mmol/L) at baseline after 7 days dapagliflozin treatment. A pharmacodynamic model was developed to describe for both groups then used estimate these parameters from individual titration curves.At baseline, diabetic had elevated TmG, threshold compared controls. Dapagliflozin treatment TmG splay in groups. However, most significant reduction excretion control subjects.The SGLT2 inhibitor improves glycemic patients by reducing which is excreted urine.